Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: gammaray who wrote (1163)	2/2/1999 11:02:00 AM
From: KZAP	Read Replies (1) \| Respond to of 1476

Good reason to buy? <<<<<Wednesday November 11, 10:01 am Eastern Time Company Press Release SOURCE: AntexBiologics Antex Biologics Again Named One of Maryland's Fastest Growing Technology Companies by Deloitte & Touche GAITHERSBURG, Md., Nov. 11 /PRNewswire/ -- AntexBiologics has been recognized as part of the ''Deloitte & Touche Maryland Fast 50'' for 1998, which ranks the fastest growing technology companies in Maryland. Rankings are based on the percentage of revenue growth over the five-year period from 1993- 1997. Antex's increase in revenues resulted in a 16th ranking overall for 1998.>>>>> KZAP

To: gammaray who wrote (1163)	2/2/1999 9:16:00 PM
From: Amigo Mike	Read Replies (2) \| Respond to of 1476

Neil and All: In the coming days, a writeup on Antex will appear on one of the sites the Amigos write for. Here is the plain Jane version: Antex Biologics (ANTX- OTCBB) Antex's Mission and Proprietary Technology: Antex Biologics is a biopharmaceutical company dedicated to the discovery, development and commercialization of products to prevent and treat infectious diseases and related disorders. As most area aware, many bacteria have become more resistant to antibiotic treatments. Antex has pledged themselves to develop vaccines and therapeutics in this area. In an effort to give their patented technology a fighting chance, Antex has aligned themselves with 3 large a powerful organizations: 1. SmithKline Beecham ( since 1996) has agreed to fund R&D and pay milestone payments valued at up to $30 million plus royalty payments on product sales. 2. Pasteur-Merioux (since 1994) - Antex has licensed its vaccine against otitis media (ear infections) caused by H Influenzae (nontypeable). Pasteur is responsible for the clinical development of this vaccine and pays milestone payments to Antex after each trial completion. SmithKline and Pasteur and both global leaders. 3. The US Department of Defense (since 1994) entered into a Cooperative Research and Development Agreement (CRADA) to test the Campylobacter Vaccine. At present SmithKline cooperates with the US DoD to develop this vaccine. Antex is developing vaccines against common infections and has developed two proprietary technologies: ART (Adhesion-Receptor Technology) and NST (Nutriment Signal Transduction). While vaccines typically provide protection after bacteria enter the body, these new technologies are the platform for Antex vaccines that prevent infection before bacteria can penetrate tissue. The vaccines developed with these technologies could be administered orally or nasally rather than by injection. Oral administration makes vaccination less expensive and easier to receive for patients, and significantly lowers the chance of adverse reactions. Antex has 7 vaccine candidates in various stages of development. 3 are currently in human clinical trials: 1. Campylobacter Jejuni Vaccine (Phase II Human Trial - Lead research report results pending- planning for additional trial in progress) for diarrhea, gastroenteritis and acute febrile. It is estimated that 400-500 million cases globally. In the most severe cases, results could include the onset of arthritis and a disease called Guillain-Barre syndrome that attacks nerves and causes paralysis. SmithKline Beecham currently conducts the trials on this vaccine. There are no current available vaccines for Campylobacter and Antex is the only company in the world working on this bacteria. If successful, analysts project this vaccine to be worth between $200 - $400 million a year in revenue. (Source: Balto Business Journal Jan 14, 1998 ... CS First Boston Analyst) 2. Helicobacter Pylori Vaccine (Phase I Human Trail results JUST ANNOUNCED) for peptic ulcers and gastritis. If left untreated, the H Pylori bacteria is a leading cause of gastric carcinoma (stomach cancer). It is estimated that almost 100% of children 3 years or older carry the bacteria. In addition, 50% of adults over 30 are believed to be infected. Antex just announced the very positive results of the Phase I trial. We look forward to further development of this vaccine. SmithKline Beecham currently conducts the trials on this vaccine. 3. Haemophilus Influenzae (Phase I Human Trials completed) for otitis media (children's ear infections). It is estimated that 80% of all children will have experienced an episode of otitis media. Severe cases could result in meningitis. The potential here is monstrous. Imagine this vaccine added to the regimen currently given to every child in the US. Pasteur Merioux is responsible for the clinical development of this vaccine. 4. Moraxella Catarrhalis (preclinicals - about to enter Phase I .... human vaccine lots have been and are being prepared) for otitis media. Severe cases could result in meningitis. or hearing loss in children. 5. Chlamydia Trachomitis (preclinicals- nearing Phase I) is a leading cause sexually transmitted diseases. Complications include cervicitis, pelvic inflammatory disease and sterility. Chlamydia are causes trachoma which accounts for 15% of the world's cases of blindness. Antex has received two awards from the National Institutes of Health to advance the development of this vaccine. 6. Shigella (preclinicals) is a another bacteria which causes severe diarrheal and gastrointestinal disorders. 7. Neisseria (research) is a leading cause of upper respiratory disorders and meningitis. Currently, Antex owns 90 worldwide patents and 22 US patents on its proprietary vaccines and technologies. Further, Antex has several more patents awaiting issuance. Antex's share price has been languishing at very low levels for a few years. At the 1998 shareholders meeting, shareholders voted for a reverse split of the company stock at a ratio of anywhere between 1 for 4 through 1 for 10. Management has yet to effect the split as they feel the company is far undervalued and would not be beneficial to shareholders. The main purpose to effect the split is to gain a listing to a national market as Antex meets all the necessary requirements for listing with the exception of share price. Since, the reverse was approved by shareholders, the stock has continued to languish which in turn prompted management to seek other ways to boost value. In November 1998, Antex announced the buy-back of its common stock and out-licensed technology through a cashless buy-back of the Company's common stock. Antex eliminated the 7.1 million options held by an underwriter which were issued as part of the Company's 1995 Private Placement financing which would have resulted in a 33% dilution to current shareholders. These agent options were considered to be a very large reason for hte depressed share price since they were exerciseable at an average of .42 per share. The technology buy-back related to immunotherapy, oligosaccharide receptor and cancer reagent technologies, licensed to GalaGen Inc in 1992. Also at the 1998 meeting, company CEO Dr Vic Esposito announced the formation of AntexPharma. From Terri Stevens, VP of Corporate Development, AntexPharma is focusing on four project areas: 1. antibiotics (products that kill or stop growth). 2. potentiators (products that will enhance the effectiveness of other antibiotics...either known or new antibiotics). 3. modulators (products that will increase or decrease virulence of bacteria). 4. Antiflamoxidants (TM) (products that are antioxidants/antiinflammatories). Staphlococcus aureous, Enterococcus, Enterobacter and Pseudomonas and certain fungi are becoming increasing resistant. AntexPharma is focusing on these for possible therapeutic applications. We have completed an investment banking model on Antex which is used by biotechnology analysts to value companies like Antex. At present, the model values Antex at $3.55 per share today. This valuation was arrived at using the absolute lowest baseline scenarios of the current vaccine candidates. Further development of the vaccines will dramatically increase the valuation. Bottom line ....... The Amigos love this company. The combination of Antex's proprietary technology, alliances with the largest vaccine companies in the world and candidates that address the problem of bacterial resistance to current treatments and others with no current treatment make Antex very attractive for long term investment. We would caution that Antex is a wave traders delight. Over the years, Antex has little control over press releases and the stock tends to move up and down in waves during times of quiet. We would suggest that .... over time ...... it is possible to accumulate shares in Antex by buying an initial long and short term position in the stock on a wave low. As the stock trades higher, sell the short term position and wait for the next wave lower. At the next wave bottom, you could purchase more shares again both long (from 1st wave short term profits) and short term and continue to accumulate (and profit) with each wave. This strategy has worked in the past with Antex stock and we would expect it to continue until Antex nears commercialization of one of the vaccines. We would like to stress we feel Antex is a very long term investment (3-5 years) and we feel that those who employ this type of trading strategy will be very happy with their investment in a few years. Disclaimer: The Amigos hold shares in Antex Biologics and have done so for more than three years. We trade this stock for our personal accounts from time to time using the strategy shown above. The Amigos have NOT received any compensation or consideration of any kind from Antex Biologics. This writeup certainly does not address all issues but gives a nice basis from which to start. I would be more than happy to discuss this or any other questions brought to the thread. Amigo Mike